Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

Eli Lilly was hit earlier this month when rival Novartis became the second, after front-runner Pfizer, to gain FDA approval for its CDK 4/6 inhibitor Kisqali (…

Fierce 15 winner CytomX is in line for a $200 million upfront payday and potentially billions in biobucks from partner Bristol-Myers Squibb as the Big Pharma…

Researchers who worked at GlaxoSmithKline before leading RespiVert to a takeover by Johnson & Johnson have raised $30.4 million (£24.5 million) for their…

Array BioPharma has yanked its NDA to the U.S. regulator for its late-stage melanoma candidate binimetinib after the agency told the biotech its phase 3 Nemo…

The FDA has rejected AstraZeneca’s hyperkalemia drug ZS-9 for the second time in 12 months. The news marks a further blow for a program AstraZeneca saw giving…

AveXis has posted top-line data from a phase 1 trial of its gene therapy against spinal muscular atrophy (SMA). All 15 patients were event-free at 13.6 months…

R&D